Abstract
Background and Aims Cardiovascular disease (CVD) is among the leading causes of death worldwide. Discovery of new omics biomarkers could help to improve risk stratification algorithms and expand our understanding of molecular pathways contributing to the disease. Here, ASSIGN – a cardiovascular risk prediction tool recommended for use in Scotland – was examined in tandem with epigenetic and proteomic features in risk prediction models in ý12,657 participants from the Generation Scotland cohort.
Methods Previously generated DNA methylation-derived epigenetic scores (EpiScores) for 109 protein levels were considered, in addition to both measured levels and an EpiScore for cardiac troponin I (cTnI). The associations between individual protein EpiScores and the CVD risk were examined using Cox regression (ncasesý1,274; ncontrolsý11,383) and visualised in a tailored R application. Splitting the cohort into independent training (n=6,880) and test (n=3,659) subsets, a composite CVD EpiScore was then developed.
Results Sixty-five protein EpiScores were associated with incident CVD independently of ASSIGN and the measured concentration of cTnI (P<0.05), over a follow up of up to 16 years of electronic health record linkage. The most significant EpiScores were for proteins involved in metabolic, immune response and tissue development/regeneration pathways. A composite CVD EpiScore (based on 45 protein EpiScores) was a significant predictor of CVD risk independent of ASSIGN and the concentration of cTnI (Hazard Ratio HR=1.32, P=3.7×10-3, 0.3% increase in C-statistic).
Conclusions EpiScores for circulating protein levels are associated with CVD risk independent of traditional risk factors and may increase our understanding of the aetiology of the disease.
Structural graphical abstract ASSIGN – a cardiovascular risk prediction tool recommended for use in Scotland – was examined in tandem with epigenetic and proteomic features in risk prediction models in ζ12,657 participants from the Generation Scotland cohort. Cox regression was used to model the association between individual predictors and CVD hospitalisation events ascertained over 16 years of follow-up. Finally, a composite protein EpiScore was developed (based on the protein EpiScores) and its predictive performance was tested. CVD – Cardiovascular Disease, EpiScore – Epigenetic Score, Cox PH – Cox Proportional Hazards Regression, DNAm – DNA methylation.
Competing Interest Statement
R.E.M. and L.M. have received a speaker fee from Illumina. R.E.M. is an advisor to the Epigenetic Clock Development Foundation. D.A.G. and R.E.M. have received consultancy fees from Optima partners. All other authors declare no competing interests.
Funding Statement
This research was funded in whole, or in part, by the Wellcome Trust (104036/Z/14/Z, 108890/Z/15/Z, 220857/Z/20/Z, and 216767/Z/19/Z). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. A.D.C is supported by a Medical Research Council PhD Studentship in Precision Medicine with funding by the Medical Research Council Doctoral Training Programme and the University of Edinburgh College of Medicine and Veterinary Medicine.
D.A.G. is funded by the Wellcome Trust 4-year PhD in Translational Neuroscience-training the next generation of basic neuroscientists to embrace clinical research (108890/Z/15/Z). E.B. and R.E.M. are supported by the Alzheimer's Society major project grant AS-PG-19b-010.
Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). Genotyping and DNA methylation profiling of the GS samples was carried out by the Genetics Core Laboratory at the Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Reference 104036/Z/14/Z, 220857/Z/20/Z, and 216767/Z/19/Z). The DNA methylation profiling and analysis was supported by Wellcome Investigator Award 220857/Z/20/Z and Grant 104036/Z/14/Z (PI: AM McIntosh) and through funding from NARSAD (Ref: 27404; awardee: Dr DM Howard) and the Royal College of Physicians of Edinburgh (Sim Fellowship; Awardee: Dr HC Whalley). All components of GS:SFHS, including the protocol and written study materials, have received formal, national ethical approval from NHS Tayside Research Ethics Committee (REC reference number 05/S1401/89). In addition local approval has been obtained from NHS Glasgow Research Ethics Committee, and from NHS Glasgow and NHS Tayside Research and Development Offices, as is required
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All components of GS:SFHS, including the protocol and written study materials, have received formal, national ethical approval from NHS Tayside Research Ethics Committee (REC reference number 05/S1401/89). In addition local approval has been obtained from NHS Glasgow Research Ethics Committee, and from NHS Glasgow and NHS Tayside Research and Development Offices, as is required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
- Results section: EpiScore models further adjusted for the concentration of cardiac troponin I - Figure 1 revised to include models corrected for ASSIGN and the concentration of cardiac troponin I - Section on EpiScores associated with CVD expanded
Data Availability
All code used in the analyses is available with open access at the following Gitlab repository: https://github.com/aleksandra-chybowska/troponin_episcores. The source datasets analysed during the current study are not publicly available due to them containing information that could compromise participant consent and confidentiality. Data can be obtained from the data owners. Instructions for accessing Generation Scotland data can be found here: https://www.ed.ac.uk/generation-scotland/for-researchers/access; the 'GS Access Request Form' can be downloaded from this site. Completed request forms must be sent to access{at}generationscotland.org to be approved by the Generation Scotland access committee. Videos introducing the 109 protein EpiScores and MethylDetectR application are available at https://www.youtube.com/channel/UCxQrFFTIItF25YKfJTXuumQ.
